This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of effectiveness was conducted in three ways. The first merely calculated the costs and survival of each of the three categories of patient. The second analysis used a prognostic model to compare and predict the costs and survival for patients who received transplantation had they not received transplantation. The third analysis compared patients awaiting transplant with those who received a transplant. The primary health outcome was survival.
Effectiveness results
The mean survival over 30 months for patients who fulfilled the criteria for transplantation was 1.77 years (95% confidence interval, CI: 1.94 to 2.43) (these figures match those reported in the trial, which appear to be in error as the mean estimate lies outside the confidence limits).
The mean survival over 30 months among patients not requiring transplant was 2.33 years (95% CI: 1.33 to 2.14) (again, these figures match those reported in the study).
All patients who were categorised as terminally ill died before the 30-month follow-up. Mean survival was 0.31 years (95% CI: 0.13 to 0.48).
The prognostic model was applied to the 14 patients who received a transplant. It estimated that transplantation increased survival by 0.12 years (95% CI: -0.52 to 0.74).
The "intent-to-treat" model was applied to the 23 patients who fulfilled the criteria for transplantation (including the 14 that went on to receive transplant). It estimated that transplantation reduced survival by 0.24 years (95% CI: -0.93 to 0.45).
Clinical conclusions
The authors concluded that the prognostic model was likely to be less biased than the intent-to-treat analysis, as allocation of transplant organs to recipients was not randomised. They concluded that the analysis suggested that SBTx was life-extending, but the small size of the study meant that it should only be provided in the context of further assessment of the technology.
Modelling
A prognostic model was used to estimate what the survival and costs for patients who received transplants would have been had they not undergone transplantation. This model was used to calculate cost-effectiveness in the "prognostic model" analysis. The prognostic model included patient age and prothrombin times, and it was assumed that patient costs in the absence of transplantation would be the same as their pre-transplantation costs. An "intent-to-treat" model estimated cost-effectiveness by comparing the costs and outcomes of patients who received transplantation with the costs and outcomes of patients awaiting transplantation.
Measure of benefits used in the economic analysis
The measure of benefits used was the life-years gained.
physician and dietician attendances, laboratory tests, medication, treatments and blood products received, details of parenteral and enteral nutrition, and length of transplant operation. The costs and the quantities were not reported separately. Local unit costs were obtained from Birmingham Children's Hospital and the price year was reported as 1998/99. A discount rate of 3.5% per annum was applied to the costs, which was in line with UK guidelines. The study reported the average costs. Medical staff time costs were not included beyond those already incorporated in the unit costs of inpatient stay, outpatient stay and transplant operation.
Statistical analysis of costs
Lin's method was used to adjust for censored cost data. A non-parametric bootstrapping method was used to generate confidence limits around mean estimates. This is appropriate when data are skewed, as is common with cost data. The bootstrapped estimates were also used to demonstrate the distribution of incremental cost-effectiveness ratios.
Indirect Costs
The indirect costs were not included in the analysis.
Currency
UK pounds sterling ().
Sensitivity analysis
Two alternative analyses were applied to calculate the cost-effectiveness of SBTx in the absence of randomised, controlled data: the "prognostic" model and the "intent-to-treat" model.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The mean cost over 30 months was 207,000 (95% CI: 168,000 to 253,000) for patients who fulfilled the criteria for transplantation, 159,000 (95% CI: 125,000 to 199,000) for patients not requiring transplantation, and 56,000 (95% CI: 12,000 to 171,000) for patients categorised as terminally ill. The cost per day was highest for patients categorised as terminally ill.
The results of the "prognostic" model indicated that transplantation reduced costs by 50,495 (95% CI: -49,448 to 38,301) over 30 months in comparison with parenteral nutrition. The results of the "intent-to-treat" model indicated that transplantation increased costs by 131,307 (95% CI: 51,450 to 211,517) in comparison with parenteral nutrition. A discount rate of 3.5% per annum was applied in these calculations.
Synthesis of costs and benefits
The costs and benefits were synthesised in order to calculate the cost per life-year gained.
The results of the "prognostic" model indicated that SBTx was dominant (i.e. more effective and less costly) than parenteral nutrition. On the cost-effectiveness plane 57% of ratios indicated that SBTx was dominant, while 29% indicated that it might be cost-saving but less effective than parenteral nutrition.
The results of the "intent-to-treat" model indicated that SBTx was dominated (i.e. more costly and less effective) by parenteral nutrition. On the cost-effectiveness plane 77% of ratios indicated that SBTx was dominated, while 23% indicated that SBTx may be cost-effective compared with parenteral nutrition, depending on the willingness-to-pay per life-year gained.
